Targeting dendritic cells with antigen-containing liposomes: antitumour immunity

Bibliography

• BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392:245–252.
   PubMed Web of Science ®Google Scholar
• WU B, WU J-M, MIAGKOV A et al.: Specific immunotherapy by genetically engineered APCs: the 'guided missile' strategy. J. haamunol. (2001) 166:4773–4779.
   Google Scholar
• 'T HART BA, VAN KOOYK Y: Yin-Yang regulation of autoimmunity by DCs. Trends Immunol (2004) 25(7):353–359.
   Google Scholar
• GILBOA E, NAIR SK, LYERLY HK: Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother. (1998) 46:82–87.
   PubMed Web of Science ®Google Scholar
• •References [4-8]. These reviews provide a good overview of DC irnmunobiology and the use of DCs in cancer immunotherapy.
   Google Scholar
• CERUNDOLO V, HERMANS IF,SALIO M: Dendritic cells: a journey from laboratory to clinic. Nat. ham-tuna (2004) 5(1):7–10.
   Google Scholar
• •See [4].
   Google Scholar
• FIGDOR CG, DE VRIES IJ,LESTERHUIS WJ, MELIEF CJ: Dendritic cell immunotherapy: mapping the way. Nat. Med. (2004) 10(5):475–480.
   PubMed Web of Science ®Google Scholar
• •See [4].
   Google Scholar
• WHITESIDE TL, ODOUX C: Dendriticcell biology and cancer therapy. Cancer Immunol Immunother. (2004) 53:240–248.
   PubMed Web of Science ®Google Scholar
• •See [4].
   Google Scholar
• ARDAVIN C, AMIGORENA S,REIS E SOUSA C: Dendritic cells: immunobiology and cancer immunotherapy. Immunity (2004) 20:17–23.
   PubMedGoogle Scholar
• •See [4].
   Google Scholar
• PACZESNY S, UENO H, FAY J, BANCHEREAU J, PALUCKA AK: Dendritic cells as vectors for immunotherapy of cancer. Semin. Cancer Biol. (2003) 13(6):439–447.
   PubMed Web of Science ®Google Scholar
• MORISAKI T, MATSUMOTO K, ONISHI H et al.: Dendritic cell-based combined immunotherapy with autologous tumour-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum. Cell (2003) 16(4):175–182.
   PubMedGoogle Scholar
• TURTLE CJ, HART DN: Dendritic cells in tumour immunology andimmunotherapy. Curt Drug Targets (2004) 5(1):17–39.
   PubMed Web of Science ®Google Scholar
• ZHOU Y, BOSCH ML,SALGALLER ML: Current methods for loading dendritic cells with tumour antigen for the induction of antitumour immunity. Immunother. (2002) 25(4):289–303.
   Web of Science ®Google Scholar
• BONIFAZ L, BONNYAY D, MAHNKE K et al.: Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8' T cell tolerance. Exp. Med. (2002) 196(12):1627–1638.
   PubMed Web of Science ®Google Scholar
• ••References [13,55]. Pioneering workshowing that DC-targeted antigen, in the absence of additional DC stimulation, can lead to T cell deletion and tolerance or unresponsiveness.
   Google Scholar
• ALVING CR: Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim. Biophys. Acta (1992) 1113:307–322.
   PubMed Web of Science ®Google Scholar
• •Reviews early work on the immune response to protein and liposomal lipid antigens.
   Google Scholar
• ULRICH AS: Biophysical aspects of using liposomes as delivery vehicles. Biosci. Rep. (2002) 22(2):129–150.
   PubMed Web of Science ®Google Scholar
• CHIKH G,SCHUTZE-REDELMEIER MP: Liposomal delivery of CTL epitopes to dendritic cells. Biosci. Rep. (2002) 22(2):339–353.
   PubMed Web of Science ®Google Scholar
• COPLAND MJ, BAIRD MA, RADES T et al.: Liposomal delivery of antigen to human dendritic cells. Vaccine (2003) 21:883–890.
   PubMed Web of Science ®Google Scholar
• SHARMA A, SHARMA US: Liposomes in drug delivery: progress and limitations. Int. J. Pharmacem. (1997) 154:123–140.
   Web of Science ®Google Scholar
• BOON T, COULIE PG,VAN DEN EYNDE B: Tumour antigens recognized by T cells. Immunol Today (1997) 18(6):267–268.
   PubMedGoogle Scholar
• NAGORSEN D, SCHEIBENBOGEN C, MARINCOLA FM, LETSCH A, KEILHOLZ U: Natural T cell immunity against cancer. Clin. Cancer Res. (2003) 9(12):4296–4303.
   PubMed Web of Science ®Google Scholar
• LEWIS JD, REILLY BD, BRIGHT RK:Tumour-associated antigens: from discovery to immunity. hat Rev. Immunol (2003) 22(2):81–112.
   Web of Science ®Google Scholar
• •An extensive review on tumour-associated antigens.
   Google Scholar
• LIU G, YING H, ZENG G et al: HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. (2004) 64(14)4980–4986.
   Google Scholar
• RIDGE JP, DI ROSA F, MATZINGER P: A conditioned dendritic cell can be a temporal bridge between a CD4' T-helper and a T-killer cell. Nature (1998) 393:474–477.
   PubMed Web of Science ®Google Scholar
• FERLAZZO G, TSANG ML,MORETTA L et al: Human dendritic cells activate resting natural killer (NK) cells and are recognised via the NKp30 receptor by activated NK cells. J. Exp. Med. (2002) 195(3):343–351.
   PubMed Web of Science ®Google Scholar
• HEATH WR, BELZ GT, BEHRENS GM et al.: Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. haamunol. Rev (2004) 199:9–26.
   PubMed Web of Science ®Google Scholar
• •An extensive review covering different aspects of the role of DCs in the induction of immunity.
   Google Scholar
• KADOWAKI N, HO S, ANTONENKO S et al.: Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. Exp. Med. (2001) 194(6):863–869.
   PubMed Web of Science ®Google Scholar
• REIS E SOUSA C, STAHL PD,AUSTYN JM: Phagocytosis of antigens byLangerhans cells in vitro. I Exp. Med. (1993) 178:509–519.
   PubMed Web of Science ®Google Scholar
• BILSLAND CA, DIAMOND MS, SPRINGER TA: The leukocyte integrin p150,95 (CD11c/CD18) as a receptor for iC3b: activation by a heterologous beta subunit and localization of a ligand recognition site to the I domain. Immunol. (1994) 152:4582–4589.
   Web of Science ®Google Scholar
• JIANG W, SWIGGARD WJ,HEUFLER C et al.: The receptor DEC-205 expressed by dendritic cells and thymic epithelium cells is involved in antigen processing. Nature (1995) 375:151–155.
   Google Scholar
• MAHNKE K, GUO M, LEES et al: Thedendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. I Cell Biol. (2000) 151:673–684.
   Web of Science ®Google Scholar
• GEIJTENBEEK TB, KROOSHOOP DJ,BLEIJS DA et al: DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. Nat. haamunol. (2000) 1(4):353–357.
   PubMed Web of Science ®Google Scholar
• BLEIJS DA, GEIJTENBEEK TB, FIGDOR CG, VAN KOOYK Y: DC-SIGN and LFA-1: a battle for ligand. Trends Immunol. (2001) 22(8):457–463.
   PubMed Web of Science ®Google Scholar
• ENGERING A, GEIJTENBEEK TB, VAN VLIET SJ et al.: The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells.' Immunol. (2002) 168:2118–2126.
   Google Scholar
• TSAN MF, GAO B: Endogenous ligands of Toll-like receptors. Leukoc. Biol. (2004) 76(3):514–519.
   PubMed Web of Science ®Google Scholar
• WAGNER H: The immunobiology of the TLR9 subfamily. Trends Immunol. (2004) 25(7):381–386.
   PubMed Web of Science ®Google Scholar
• SKOBERNE M, BEIGNON AS, BHARDWAJ N: Danger signals: a time and space continuum. Trends Mol. Med. (2004) 10(6):251–257.
   PubMed Web of Science ®Google Scholar
• GORDON S: Pattern recognition receptors, doubling up for the innate immune response. Cell (2002) 111:927–930.
   PubMed Web of Science ®Google Scholar
• YANG Y, HUANG CT, HUANG X, PARDOLL DM: Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. (2004) 5(5):508–515.
   PubMed Web of Science ®Google Scholar
• •This paper shows that T cell tolerance to tumour antigens may be reversed by persistent stimulation of TLRs on DCs.
   Google Scholar
• PAN J, ZHANG M, WANG Jet al.: Interferon-y is an autocrine mediator for dendritic cell maturation. Immunol. Lett. (2004) 94:141–151.
   Google Scholar
• HIRAMOTO JS, TSUNG K,BED OLLI M, NORTON JA, HIROSE R: Antitumour immunity induced by dendritic cell-based vaccination is dependent on interferon-y and interleukin-1 2. 1. Surg. Res. (2004) 116:64–69.
   Google Scholar
• KUPPNER MC, GASTPAR R,GELWER S et al.: The role of heat shock protein (hsp70) in dendritic cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur. Immunol. (2001) 31(5):1602–1609.
   Google Scholar
• MANJILI MH, WANG X-Y, MACDONALD IJ et al.: Cancer immunotherapy and heat-shock proteins: promises and challenges. Expert Opin. Biol. Ther. (2004) 4(3):363–373.
   PubMed Web of Science ®Google Scholar
• BODEY B, SIEGEL SE, KAISER HE: Antigen presentation by dendritic cells and their significance in antineoplasticimmunotherapy. Ira Vivo (2004) 18(1):81–100.
   PubMed Web of Science ®Google Scholar
• HANSON HL, DONERMEYER DL, IKEDA H et al.: Eradication of established tumours by CD8' T cell adoptive immunotherapy. Immunity (2000) 13:265–276.
   PubMed Web of Science ®Google Scholar
• FOSS FM: Immunologic mechanisms of antitumour activity. Semin. Oncol. (2002) 29(3 Suppl. 7):5–11.
   Google Scholar
• MATSUI K, O& MARA LA, ALLEN PM: Successful elimination of large established tumours and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. hat. Immunol. (2003) 15(7):797–805.
   Web of Science ®Google Scholar
• VUILLIER F, MALOUM K,THOMAS EK et al.: Idiotype-pulsed dendritic cells are able to induce antitumoural cytotoxic CD8' cells in chronic lymphocytic leukaemia. ELI: Haematol. (2003) 120(2):243–250.
   Google Scholar
• YEE C, THOMPSON JA, BYRD D et al.: Adoptive T cell therapy using antigen-specific CD8' T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumour effect of transferred T cells. Proc. Natl. Acad. Sci. USA (2002) 99(25):16168–16173.
   PubMed Web of Science ®Google Scholar
• GAO FG, KHAMMANIVONG V, LIU WJ et al.: Antigen-specific CD4' T-cell help is required to activate a memory CD8' T cell to a fully functional tumour killer cell. Cancer Res. (2002) 62(22):6438–6441.
   PubMed Web of Science ®Google Scholar
• MATTES J, HULETT M, XIE W et al.: Immunotherapy of cytotoxic T cell-resistant tumours by T helper 2 cells: an eotaxin and STAT6-dependent process. I Exp. Med. (2003) 197(3):387–393.
   PubMed Web of Science ®Google Scholar
• BOUSSO P, ROBEY E: Dynamics of CD8' T cell priming by dendritic cells in intact lymph nodes. Nat. Immunol. (2003) 4:579–585.
   PubMed Web of Science ®Google Scholar
• MILLER MJ, HEJAZI AS, WEI SH, CAHALAN MD, PARKER I: T cell repertoire scanning is promoted by dynamic dendritic cell behaviour and random T cell motility in the lymph node. Proc. Natl. Acad. Sci. USA (2004) 101:998–1003.
   PubMed Web of Science ®Google Scholar
• FUJII S-I, SHIMIZU K, SMITH C, BONIFAZ L, STEINMAN RM: Activation of natural killer T cells by a-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to aco-administered protein. I. Exp. Med. (2003) 198(2):267–279.
   PubMed Web of Science ®Google Scholar
• LIU K, IYODA T, SATERNUS M et al.:Immune tolerance after delivery of dying cells to dendritic cells in situ. I Exp. Med. (2002) 196(8):1091–1097.
   PubMed Web of Science ®Google Scholar
• HAWIGER D, INABA K, DORSETT Y et al.: Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. I Exp. Med. (2001) 194(6):769–779.
   PubMed Web of Science ®Google Scholar
• •See [13].
   Google Scholar
• TAAMS LS, WAUBEN MH: Anergic T cells as active regulators of the immune response. Hum. Immunol. (2000) 61:633–639.
   PubMed Web of Science ®Google Scholar
• APPLEMAN LJ, BOUSSIOTIS VA: T cell anergy and costimulation. Immunol. Rev. (2003) 192:161–180.
   PubMed Web of Science ®Google Scholar
• RUTELLA S, LEMOLI RM: Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunol. Lett. (2004) 94:11–26.
   PubMed Web of Science ®Google Scholar
• BEDROSIAN I, MICK R, XU S et al.: Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. I Clin. Oncol. (2003) 21(203826–3835.
   Google Scholar
• GABIZON A, PAPAHADJOPOULOS D: The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta (1992) 1103:94–100.
   PubMed Web of Science ®Google Scholar
• ••References [60–63,65]. Studies thatcharacterise the properties of sterically stabilised liposomes having extended circulation times in vivo.
   Google Scholar
• LEE KD, HONG K,PAPAHADJOPOULOS D: Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim. Biophys. Acta (1992) 1103:185–197.
   PubMed Web of Science ®Google Scholar
• ••See [60].
   Google Scholar
• MARUYAMA K, KENNEL SJ, HUANG L: Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proc. Nati Acad. Sci. USA (1990) 87:5744–5748.
   PubMed Web of Science ®Google Scholar
• ••See [60].
   Google Scholar
• PAPAHADJOPOULOS D, ALLEN TM, GABIZON A et al.: Sterically stabilized liposomes: improvements in pharmacokinetics and antitumour therapeutic efficacy. Proc. Nati Acad. Sci. USA (1991) 88:11460-11464. See [60].
   Google Scholar
• LASIC DD, PAPAHADJOPOULOS D: Liposomes revisited. Science (1995) 267:1275–1276.
   PubMed Web of Science ®Google Scholar
• ALLEN TM, HANSEN C, MARTIN F, REDEMANN C, YAU-YOUNG A: Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochlin. Biophys. Acta (1991) 1066:29–36.
   PubMed Web of Science ®Google Scholar
• ••See [60].
   Google Scholar
• LASIC DD, MARTIN FJ, GABIZON A, HUANG SK, PAPAHADJOPOULOS D:Sterically stabilized liposomes: a hypothesis of the molecular origin of the extended circulation times. Biochlin. Biophys. Acta (1991) 1070:187–192.
   PubMed Web of Science ®Google Scholar
• ALVING CR: Liposomes as carriers of antigen and adjuvant. Inonunol. Meth. (1990) 140:1–13.
   Google Scholar
• SHAHUM E, THE. RIEN HM: Effect of liposomal antigens on the priming and activation of the immune system by dendritic cells. mt. brununophann. (2002) 2:591–601.
   Google Scholar
• GREGORIADIS G: The immunological adjuvant and vaccine carrier properties of liposomes. Drug Target. (1994) 2:351–356.
   PubMed Web of Science ®Google Scholar
• AMBROSCH F, WIEDERMANN G, JONAS S et al.: Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine (1997) 15:1209–1213.
   PubMed Web of Science ®Google Scholar
• YUKIHIKO A, HIROYUKI S, SEISHI T: Interferon-y inductive effect of liposomes as an immunoadjuvant. Vaccine (1995) 13(18): 1809–1814.
   PubMed Web of Science ®Google Scholar
• LENARCZYK A, LE TT, DRANE D, MALLIAROS J et al.: ISCOM based vaccines for cancer immunotherapy. Vaccine (2004) 22(8):963–974.
   PubMed Web of Science ®Google Scholar
• BUNGENER L, HUCKRIEDE A, WILSCHUT J, DAEMEN T: Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMS. Biosci. Rep. (2002) 22(2): 323–338.
   PubMed Web of Science ®Google Scholar
• SCHUMACHER R, ADAMINA M, ZURBRIGGEN R et al.: Influenza virosomes enhance class I restricted CTL induction through CD4' T cell activation. Vaccine (2004) 22:715–724.
   Google Scholar
• IGNATIUS R, MAHNKE K, RIVERA M et al.: Presentation of proteins encapsulated in sterically stabilized liposomes bydendritic cells initiates CD8' T-cell responses in vivo. Blood (2000) 96(10):3505–3513.This paper shows that antigen encapsulated in sterically stabilised liposomes can be presented by DCs in vitro and in vivo to activate T cells.
   Google Scholar
• ADAMINA M, BOLLI M, ALBO F et al.: Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes. Br. Cancer (2004) 90(1):263–269.
   Google Scholar
• CAVAZZA A, ADAMINA M, AUSIELLO CM et al. Hydrolysis of the tumour-associated antigen epitope gp 1 00280 288 by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells. Clin. brununol. (2004) 111:252–261.
   Google Scholar
• ALBO F, CAVAZZA A, GIARDINA B et al.: Degradation of the tumour antigen epitope gp100(280-288) by fibroblast-associated enzymes abolishes specific immunorecognition. Biochint Biophys. Acta (2004) 1671:59–69.
   PubMed Web of Science ®Google Scholar
• COLLINS DS, FINDLAY K,HARDING CV: Processing of exogenous liposome-encapsulated antigens in vivo generates class I MHC-restricted T cell responses. brununol. (1992) 148:3336–3341.
   Google Scholar
• ZHOU F, HUANG L: Liposome-mediated cytoplasmic delivery of proteins: an effective means of accessing the MHC class I-restricted antigen presentation pathway. brununomethods (1994) 4:229–235.
   PubMedGoogle Scholar
• MORON G, DADAGLIO G, LECLERC C: New tools for antigen delivery to the MHC class I pathway. Trends brununol. (2004) 25(2):92–97.
   PubMed Web of Science ®Google Scholar
• KEDAR E, PALGI 0, GOLOD G, BABAI I, BARENHOLZ Y: Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-a show improved pharmacokinetics and biological activity and reduced toxicity in mice. J.Immunother. (1997) 20(3):180–193.
   Google Scholar
• KEDAR E, GUR H, BABAI I et al: Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of Interleulkin-2 encapsulated in conventional liposomes and in long-circulating liposomes. brununother. (2000) 23(1):131–145.
   Google Scholar
• KONIGSBERG PJ, GODTEL R, KISSEL T, RICHER LL: The development of IL-2 conjugated liposomes fortherapeutic purposes. Biochlin. Biophys. Acta (1998) 1370(2):243–251.
   PubMed Web of Science ®Google Scholar
• KRUP OC, KROLL I, BOSE G, FALKENBERG FW: Cytokine depot formulations as adjuvants for tumour vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. Innnunother. (1999) 22(6):525–538.
   Google Scholar
• TEN HAGEN TL, SEYNHAEVE AL, VAN TIEL ST, RUITER DJ, EGGERMONT AM: Pegylated liposomal tumour necrosis factor-alpha results in reduced toxicity and synergistic antitumour activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int.j Cancer (2002) 97(1):115–120.
   PubMed Web of Science ®Google Scholar
• VAN SLOOTEN ML, BOERMAN 0, ROMEREN K et al.: Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects. Biochlin. Biophys. Acta (2001) 1530:134–145.
   Google Scholar
• AKBARI 0, PANJWANI N, GARCIA S et al.: DNA vaccination: transfection and activation of dendritic cells as key events for immunity. I Exp. Med. (1999) 189(1):169–177.
   Google Scholar
• SHEDLOCK DJ, WEINER DB: DNA vaccination: antigen presentation and the induction of immunity. I Leukoc. Biol. (2000) 68:793–806.
   PubMed Web of Science ®Google Scholar
• TAKASHIMA A, MORITA A: Dendritic cells in genetic immunization. Leukoc. Biol. (1999) 66:350–356.
   PubMed Web of Science ®Google Scholar
• COOMBES BK, MAHONY JB: Dendritic cell discoveries provide new insight into the cellular immunobiology of DNA vaccines. brununol. Lett. (2001) 78:103–111.
   Google Scholar
• YOU Z, HUANG X, HESTER J, TOH HC, CHEN SY: Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. (2001) 61:3704–3711.
   PubMed Web of Science ®Google Scholar
• SBAI H, SCHNEIDER J, HILL AV, WHALEN RG: Role of transfection in the priming of cytotoxic T-cells by DNA-mediated immunization. Vaccine (2002) 20:3137–3147.
   PubMed Web of Science ®Google Scholar
• ZELENAY S, ELIAS F, FLO J: Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides. Eur. brununol. (2003) 33:1382–1392.
   PubMed Web of Science ®Google Scholar
• DE LIMA MC, SIMOES S, PIRES P et al.: Gene delivery mediated by cationic liposomes: from biophysical aspects to enhancement of transfection. Mot Mem& Biol. (1999) 16:103–109.
   PubMed Web of Science ®Google Scholar
• EL-ANEED A: An overview of current delivery systems in cancer gene therapy. J. Control. Release (2004) 94:1–14.
   PubMed Web of Science ®Google Scholar
• DILEO J, BANERJEE R,WHITMORE M et al.: Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumour immune responses. Mol Ther: (2003) 7(5):640–648.
   Google Scholar
• XU L, HUANG CC, HUANG W et al.: Systemic tumour-targeted gene delivery by anti-transferrin receptor ScFv-immunoliposomes. Ma Cancer Ther (2002) 1:337–346.
   PubMed Web of Science ®Google Scholar
• SHI N, BOADO RJ, PARDRIDGE WM: Receptor-mediated gene targeting in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. (2001) 18:1091–1095.
   PubMed Web of Science ®Google Scholar
• REDDY JA, ABBURI C, HOFLAND H et al.: Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumours. Gene Ther (2002) 9:1542–1550.
   PubMed Web of Science ®Google Scholar
• CHAMARTHY SP, JIA L, KOVACS JR et al.: Gene delivery to dendritic cells facilitated by a tumour necrosis factor alpha-competing peptide. Ma Immunol (2004) 41(8):741–749.
   PubMed Web of Science ®Google Scholar
• HOWARTH M, ELLIOTT T: The processing of antigens delivered as DNA vaccines. Immunol Rev (2004) 199:27–39.
   PubMed Web of Science ®Google Scholar
• HANSEN CB, KAO GY, MOASE EH, ZALIPSKY S, ALLEN TM: Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta (1995) 1239:133–144.
   PubMed Web of Science ®Google Scholar
• ••This paper presents several methods bywhich targeting proteins, such as antibodies, can be covalently attached to sterically stabilised liposomes.
   Google Scholar
• VAN BROEKHOVEN CL, ALTIN JG: A novel system for convenient detection oflow-affinity receptor-ligand interactions: chelator-lipid liposomes engrafted with recombinant CD4 bind to cells expressing MHC class II. Immunol Cell Biol. (2001) 79:274–284.
   PubMed Web of Science ®Google Scholar
• VAN BROEKHOVEN CL, ALTIN JG: A novel approach for modifying tumour cell-derived plasma membrane vesicles to contain encapsulated IL-2 and engrafted costimulatory molecules for use in tumour immunotherapy. Int. 1 Cancer (2002) 98:63–72.
   PubMed Web of Science ®Google Scholar
• ••This paper shows that tumour cell-derivedPMVs, once engrafted with the T cell costirnulatory molecules B7.1 and CD40, can be used as a vaccine to enhance tumour immunity in syngeneic animals.
   Google Scholar
• ELAMANCHILI P, DIWAN M, CAO M, SAMUEL J: Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine (2004) 22:2406–2412.
   PubMed Web of Science ®Google Scholar
• KRISHNAN L, SAD S, PATEL GB, SPROTT GD: Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of Interleukin 12 and protect against tumour challenge. Cancer Res. (2003) 63:2526–2534.
   PubMed Web of Science ®Google Scholar
• FOGED C, ARIGATA C, SUNDBLAD A et al.: Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine (2004) 22(15-16):1903–1913.
   PubMed Web of Science ®Google Scholar
• ESPUELAS S, HALLER P, SCHUBER F, FRISCH B: Synthesis of an amphiphilic tetraantennary mannosyl conjugate and incorporation into liposome carriers. Bioorg. Med. Chem. Lett. (2003) 13:2557–2560.
   PubMed Web of Science ®Google Scholar
• ALTIN JG, WHITE FA, EASTON CJ: Synthesis of the chelator lipid nitrilotriacetic acid ditetradecylamine (NTA-DTDA) andits use with IAsys biosensor to study receptor-ligand interactions on model membranes. Biochim. Biophys. Acta (2001) 1513:131–148.
   PubMed Web of Science ®Google Scholar
• VAN BROEKHOVEN CL, PARISH CR, DEMANGEL C, BRITTON WJ, ALTIN JG: Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumour immunity and for tumour immunotherapy. Cancer Res. (2004) 64:4357–4365.
   PubMed Web of Science ®Google Scholar
• ••This paper shows that tumour-derivedPMVs can be modified to target both tumour-associated antigens and a DC maturation signal directly to DCs in vivo for enhancement of antitumour immunity.
   Google Scholar
• BONIFAZ LC, BONNYAY DP, CHARALAMBOUS A et al: In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. Exp. Med. (2004) 199(6):815–824.
   PubMed Web of Science ®Google Scholar
• ••This paper shows that a fusion proteinantigen targeted to DEC-205 on DCs in vivo elicits effective antitumour responses only when co-administered with a DC activation signal.
   Google Scholar